Navin Fluorine International Limited – Investor Presentation Summary

Key Operational Highlights

  • Consolidated sales reached ₹1,045.1 Cr in Q1 FY27, representing 44% YoY growth and 11% QoQ growth.
  • Operating EBITDA was ₹357.1 Cr, up 73% YoY and 11% QoQ, with margin expanding 566 bps YoY to 34.2%.
  • Business vertical growth drivers: HPP revenue grew 33% YoY, Specialty Chemicals grew 48% YoY, and CDMO grew 82% YoY.

Segment-wise Performance

HPP (Hydrofluoroolefins and Related Products):

  • Revenue growth driven by volume increase and higher realizations.
  • Constructive pricing environment for HFC products with increasing interest for contractual offtakes.
  • AHF facility commenced operations in Q4 FY26 and continues ramping up.

Specialty Chemicals:

  • Sustained growth supported by strong order visibility.
  • Strong product pipeline with scale-up across existing molecules and new launches.
  • Geographic mix: 62% domestic, 38% export.

CDMO (Contract Development and Manufacturing Organization):

  • Strong momentum backed by order book and deeper engagement with European CDMO major.
  • Expanding footprint in customer supply chain with increasing demand for existing molecule.
  • Geographic mix: 98% export, 2% domestic.
  • Balanced portfolio with mix of late/commercial and early-stage molecules across therapeutic areas (Oncology, Respiratory, Cardiovascular, Neurology, Animal Health).

Financial Highlights

Consolidated Financials (₹ Crores):

  • Revenue: ₹1,045.08 (Q1 FY27), ₹725.40 (Q1 FY26), ₹937.71 (Q4 FY26)
  • Operating EBITDA: ₹357.07 (Q1 FY27), ₹206.79 (Q1 FY26), ₹321.15 (Q4 FY26)
  • PAT: ₹243.31 (Q1 FY27), ₹117.17 (Q1 FY26), ₹212.62 (Q4 FY26)
  • EPS: Not specified
  • Margins: Operating EBITDA Margin 34.2% (Q1 FY27), 28.5% (Q1 FY26), 34.2% (Q4 FY26); Operating PBT Margin 27.1% (Q1 FY27), 19.5% (Q1 FY26), 26.8% (Q4 FY26)
  • YoY/QoQ comparison: Revenue +44% YoY/+11% QoQ; Operating EBITDA +73% YoY/+11% QoQ; PAT +108% YoY/+14% QoQ
  • Drivers of financial performance: Volume growth, higher realizations, operational efficiencies

Standalone Financials (₹ Crores):

  • Revenue: ₹694.68 (Q1 FY27), ₹542.95 (Q1 FY26)
  • Operating EBITDA: ₹244.98 (Q1 FY27), ₹154.20 (Q1 FY26)
  • PAT: ₹190.64 (Q1 FY27), ₹112.76 (Q1 FY26)

Geographical Revenue Split

Specialty Chemicals: Domestic 62%, Export 38%

CDMO: Export 98%, Domestic 2%

Regional Breakdown: Not specified

Balance Sheet Snapshot

Net Debt/Equity: Not specified

Reserves: Not specified

Current Assets/Liabilities: Not specified

Working Capital/Leverage Metrics: Not specified

Financial Health Insights: Not specified

Capex & Cash Flow Health

Ongoing Capex Program:

  • HFC Expansion: ₹236.5 Cr for additional capacity equivalent to 15,000 MTPA of R32, commissioned by Q3 FY27, peak revenue potential ₹600-825 Cr per annum
  • MPP De-bottlenecking: ₹75 Cr for Dahej capacity expansion, commissioned by Q3 FY27, peak revenue potential ₹140-160 Cr per annum
  • Chemours Project: ₹120 Cr (35% customer funded) for advanced materials, commissioned by Q2 FY27
  • Renewable Power: ₹15.73 Cr for 14.9 MW hybrid capacity across NFIL & NFASL
  • CDMO cGMP4: Phase II capex of ₹125 Cr expected operational by Q4 FY27

Capital Expenditure: Total ongoing capex over ₹436 Cr

Free Cash Flow: Not specified

Operating Cash Flow: Not specified

Net Debt Movement: Not specified

Investment Rationale: Capacity expansion, technology upgrades, sustainability goals

Strategic & R&D Initiatives

Incubating Advanced Materials:

  • Developing new high-growth, high-margin business vertical focusing on niche applications in Data Centers, Electronics, Defence & Semiconductors
  • Building on core fluorination capabilities

R&D Investments:

  • Total R&D spend in FY26: ₹48.71 Cr
  • 3 Modern R&D Centers: Surat, Gujarat (65 chemists, 40 engineers); Dewas, MP (70 team members); Runcorn, Manchester (18 team members)
  • Focus on complex KSMs for global pharma and biotech innovators
  • Digital transformation through Electronic Lab Notebooks (ELN) and LIMS implementation

Strategic Rationale: Expanding into high-growth markets, reducing operational costs, strengthening technology leadership

Industry Trends & Business Environment

Macro/Industry Trends: Constructive global demand-supply environment driven by transition to low GWP gasses and increasing RAC and blends demand in India and export market

Impact on Company: Positive pricing environment for HFC products, increasing demand for fluorinated specialty chemicals

Management Commentary & Growth Outlook

Strategic Outlook: Continued growth across all business verticals supported by strong order book and pipeline

FY Guidance: Not specified

Market Share Targets: Not specified

Risks and Opportunities: Not specified

ESG Updates

Sustainability Goals Progress (FY 2025-26):

  • Environmental: 100% compliance with EPR requirements for Plastic Packaging Materials; 11.1% increase in specific carbon emissions; 12.15% renewable electricity usage; engaged with 30% of value chain partners
  • Social: 3.94% workplace diversity; 0% gender diversity in leadership teams; 10% gender diversity in Board of Directors
  • Governance: 89.24% resolution of complaints; zero cases of corruption and bribery

CSR Initiatives:

  • Total CSR spend in FY25-26: ₹8.72 Cr
  • Partners: Shri Sadguru Seva Sangh Trust, Blind People's Association, Shakti Foundation, Charutar Arogya Mandal's Shri Krishna Hospital, Sir J. J. Hospital

Digital Transformation

Advancing digitalization through planned implementation of Electronic Lab Notebooks (ELN) and LIMS to improve efficiency, traceability and compliance.